stockportfolio.pro
Stocks / GERN vs NNNN
GERN vs NNNN
Geron Corporation and Anbio Biotechnology side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Geron Corporation (GERN) | Anbio Biotechnology (NNNN) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $183.88M | $8.65M |
| Net income (latest FY) | $-83.50M | $6.40M |
| Revenue growth (5y CAGR) | 273.5% | -28.4% |
| Net margin | -45.4% | 74.1% |
| Return on equity | -37.0% | 21.2% |
| P/E ratio | — | 107.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GERN — free Open NNNN — freeFrequently asked questions
Which is bigger, GERN or NNNN?
Geron Corporation is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, GERN or NNNN?
Over the last five fiscal years, Geron Corporation grew revenue faster — 273.5%/yr versus -28.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.